Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
Investor's Business Daily on MSN3h
GSK Surges 7% After Bumping Its 2031 Outlook To North Of $50 BillionGSK stock rocketed Wednesday after the pharma titan raised its 2031 sales outlook to north of $50 billion.Please watch the ...
GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...
Key Takeaways GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and ...
Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...
The pharmaceutical company citied promising pipeline developments and said cancer treatments drove above-expected growth.
The pharmaceutical giant targets an increase in core operating profit of between 6% and 8% in 2025, after cancer treatments ...
GSK's Q4 sales hit $10.40 billion, topping estimates. Specialty Medicines grew 14%, while vaccines declined. The company ...
GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines including cancer and HIV drugs, sending shares up as much as 6 per cent on ...
As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback